查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1830288

Castleman氏病治療市場（按治療類型、治療線、分銷管道和最終用戶分類）—2025-2032 年全球預測

Castleman Disease Treatment Market by Treatment Type, Line Of Therapy, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年， Castleman氏病治療市場規模將成長至 9.5452 億美元，複合年成長率為 14.01%。

主要市場統計數據
基準年2024年 3.3415億美元
預計2025年 3.8066億美元
預測年份：2032年 9.5452億美元
複合年成長率（%） 14.01%

對Castleman氏病的臨床複雜性以及影響治療決策的不斷發展的治療和護理框架的策略概述

Castleman氏病帶來了複雜的臨床和商業挑戰，涵蓋免疫學、腫瘤學和罕見疾病管理。患者表現出多種疾病表現，從可局部治療的單中心疾病到需要多學科治療的多中心全身性疾病。延遲診斷和異質性臨床表現增加了未滿足的醫療需求，而細胞激素訊號傳導作用的持續演變也顯著改變了臨床治療重點。

過去十年，治療策略已從經驗性地廣泛使用免疫抑制和細胞毒性療法，轉變為生物目標干預，從而改變了許多患者的病程。隨著藥物學創新的推進，醫療服務模式也不斷發展，涵蓋居家治療、跨學科臨床合作以及旨在提高患者生活品質和依從性的綜合患者支持機制。由於相關人員關注臨床影響和操作可行性，治療領域需要製定能夠協調科學進步與可近性、報銷和實際應用等現實情況的策略。

重塑Castleman氏病治療的最重大轉變源自於生物目標、生物標記主導策略和新型治療模式

近期機制和治療方法的進展改變了研究、臨床和患者支持模式。對白細胞介素-6通路和細胞激素調控的密切關注，已將研究投入轉向生物製藥和單株抗體，而生物標記發現方面的同步努力旨在對患者進行分層，以便進行更有針對性的干涉，並識別出最有可能獲得持久獲益的患者。這種科學關注正在引發一系列下游變革，影響研究設計、對照藥物選擇和監管交互作用。

同時，醫療服務交付領域的創新正在加速。居家管理、遠端醫療追蹤和綜合專科診所網路的興起重塑了病患的參與度和依從性。伴隨這些變化的是支付方和醫療服務提供者的調整，強調基於價值的合約和基於結果的證據。總而言之，這些轉變要求相關人員重新評估臨床路徑、供應鏈韌性和商業策略，以更好地關注目標有效性、以患者為中心的交付方式以及可衡量的現實世界結果。

2025 年美國關稅政策的變化將如何影響Castleman氏病藥物供應鏈、籌資策略和取得的連續性

2025年美國關稅調整為參與治療罕見免疫介導疾病的製造商、經銷商和醫療保健提供者帶來了新的考量。即使核心生物製藥本身是在特殊貿易條款下生產的，活性藥物原料藥、一次性器械、包裝組件和低溫運輸物流等輔助投入也容易受到跨境成本轉移的影響。進口關稅和物流額外費用的變化迫使相關人員重新評估採購決策和庫存策略，以維持對弱勢患者群體的持續照護。

在實踐中，這些供應側的成本壓力可能促使製造商考慮近岸外包、尋找合格的替代供應商或加強垂直整合，以控制價值鏈中的關鍵節點。醫療系統和專科藥房的應對措施是縮短採購週期並增強緩衝能力，以降低治療中斷的風險。從商業性角度來看，定價、合約和病患援助計畫的談判必須考慮到土地徵用成本上升和潛在延誤等營運現實。從策略角度來看，積極規劃關稅風險並建立靈活採購模式的機構能夠在保持藥品供應的同時，有效管理利潤率，並確保患者堅持治療。

深入的細分洞察，解釋治療類型、治療線、分銷管道和醫療保健環境如何影響臨床和商業執行

清晰地了解患者群組和治療途徑對於解讀治療反應和規劃商業性方案至關重要。治療細分區分了化療方案和生物目標，其中化療進一步透過聯合治療與單藥療法進行分析，皮質類固醇的使用則透過地塞米松和潑尼松等藥物進行區分。這種細分有助於了解廣譜免疫抑制療法與精準標靶治療的臨床前景，並支持臨床醫生決策中至關重要的安全性和耐受性比較考量。

治療線細分反映了介入措施在一線、第二線和後線治療中的定位，其中一線治療方案進一步細分為聯合治療和單藥治療策略。區分線下和線上通路可以揭示患者獲取途徑、配藥工作流程和依從性支持方面的差異。終端使用者分析可以明確護理的提供地點，例如居家照護、醫院和專科診所，並將居家照護進一步細分為自我管理和上門護理服務，以反映患者獨立性、培訓需求和監測強度方面的差異。這種細分提供了多方面的視角，有助於制定有針對性的臨床方案、最佳化供應鏈規劃並客製化服務。

美洲、歐洲、中東和非洲以及亞太地區的區域差異如何定義訪問路徑、採用模式和商業性方法？

區域動態對臨床應用、報銷策略和可近性途徑有著巨大的影響。在美洲，專科中心和成熟的轉診網路推動了靶向生技藥品的應用，並支持了穩健的臨床試驗活動。雖然這種區域生態系統有助於快速將證據推廣到實踐中，但不同醫療機構和人群在藥物可及性方面仍有差異。

歐洲、中東和非洲地區（EMEA）是一個多元化的地區，其監管環境、報銷標準和醫療保健體系結構差異巨大。在一些西歐市場，集中式專家網路和健康技術評估流程促進了實證應用。同時，亞太市場將生物製藥生產能力的快速擴張與成本敏感的支付方環境結合。雖然各國的趨勢各不相同，但它們正在推動多樣化的商業性模式，從本地製造夥伴關係到分級定價和旨在改善可及性和病患監測的數位參與模式。

公司正在採用商業和發展策略來區分治療方法、擴大獲取途徑並建立永續的證據生成項目

Castleman氏病的關鍵商業和開發策略著重於整個價值鏈的創新，而非單一的差異化點。本公司優先考慮透過標靶作用機制獲得持續的臨床效益，透過研究者主導臨床實驗和註冊性試驗拓寬適應症範圍，並在生命週期臨床實驗與產品組合多元化之間取得平衡，以降低單一產品風險。與製造商、臨床研究機構和專業藥房建立策略夥伴關係關係是擴大複雜生物製藥生產規模和簡化患者獲取途徑的常用策略。

除了研發管線和生產方面的考慮，成功的公司還在病患支援計畫、真實世界證據產生和臨床醫生教育方面進行投資，以加速產品的應用並向付款人展示其價值。定價策略擴大體現了領先標價與基於療效的合約和風險分擔模式相結合的模式。同時，生物相似藥和替代生物製藥競爭對手的進入潛力凸顯了透過卓越的安全性、便捷的給藥方式以及在真實世界中可驗證的長期療效來實現差異化的重要性。

為行業領導者提供實用的優先建議，以協調臨床創新、獲取策略和營運彈性，實現長期成功

行業領導者應優先考慮一系列整合的、可操作的舉措，將臨床有效性與可及性和營運韌性相結合。首先，對診斷準確性和生物標記項目的投資將使患者選擇更加精準，並加強付款人對話，從而減少比較有效性的不確定性。其次，實現製造和供應夥伴關係的多元化，包括區域產能和可行的替代供應商，將減少因關稅導致的成本轉移和物流中斷的風險。

第三，建立強大的病患支援基礎設施，包括家庭管理培訓、到府護理師服務和數位依從性工具，可以提高現實世界病患的依從性和臨床療效。第四，儘早與付款方合作，設計基於療效或基於價值的合約安排，有助於填補證據空白，擴大覆蓋範圍，同時協調獎勵。最後，公司應採用證據連續體方法，將隨機數據與現實世界的註冊數據和患者報告的療效相結合，以支持其長期定位和生命週期策略。

透過結合臨床文獻、相關人員訪談和真實世界數據三角測量的嚴格混合方法研究途徑獲得可靠的見解

本文的研究結果源自於混合方法研究途徑，旨在平衡臨床嚴謹性和現實世界的適用性。此調查方法整合了對同行評審文獻和臨床試驗註冊庫的全面回顧，以及對執業臨床醫生、專業藥劑師和付款人代表進行的定性訪談，以了解實踐模式和報銷促進因素。我們分析了現實世界資料來源和觀察性註冊庫證據，以檢驗治療途徑，並描述對照試驗以外的依從性和安全性概況。

為確保穩健性，我們採用了數據三角測量和交叉驗證，並透過反覆專家諮詢來解釋模糊或不一致的訊號。關鍵變量，例如治療方式、治療線、治療場所和分銷管道，均採用統一編碼，以便跨資料流進行比較分析。在整個研究過程中，我們嚴格遵守倫理和資料管治標準，並整合研究結果，以根據當前臨床實踐和營運現狀提供切實可行的見解。

將治療創新轉化為Castleman氏病持續臨床和營運影響的證據和策略方向的簡明綜合

總而言之，生物目標的進展和不斷發展的治療模式正在重塑Castleman氏病的治療格局，為相關人員帶來機會和義務。儘管圍繞細胞激素調節的科學進步已為許多患者帶來了有意義的改善，但與藥物可及性、供應鏈韌性和多變的報銷環境相關的結構性挑戰仍然存在。應對這些挑戰需要在臨床、商業和營運領域採取協調一致的行動，以確保治療成果轉化為持續的患者獲益。

展望未來，整合生物標記指導的患者選擇、靈活的籌資策略、以付款​​人為中心的價值展示以及以患者為中心的交付模式的組織將最有能力將創新轉化為現實影響。涵蓋研發、上市和核准後證據產生的整體策略，為改善Castleman氏病病患者的預後，同時維持商業性可行性和營運永續性，提供了最清晰的途徑。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 臨床實驗Situximab生物相似藥的臨床試驗進展擴大了多中心Castleman氏病的治療選擇
  • 精準醫療方法利用生物標記物來客製化Castleman氏病的治療方法，從而提高其採用率
  • 加大對以JAK-STAT訊號為標靶的小分子抑制劑在難治性Castleman氏病治療中的投入
  • 學術機構與生物製藥公司加強合作，加速Castleman氏病新型療法的開發
  • 下一代抗 IL-6 受體藥物的監管核准改變了 Castleman 症候群患者的治療前景。
  • 加強病患就醫計畫和報銷策略，以減輕治療罕見疾病的經濟負擔

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章Castleman氏病治療市場（依治療類型）

  • 化療
    • 聯合治療
    • 單一療法
  • 皮質類固醇
    • 地塞米松
    • 強的松
  • Situximab
  • 托珠單抗

第9章Castleman氏病治療市場治療線

  • 第一行
    • 聯合治療
    • 單一療法
  • 後面幾行
  • 第二行

第 10 章Castleman氏病治療市場（依通路）

  • 離線
  • 線上

第 11 章Castleman氏病治療市場：依最終使用者分類

  • 居家照護環境
    • 自我管理
    • 到府護理服務
  • 醫院
  • 專科診所

第12章Castleman氏病治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章Castleman氏病治療市場：依類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章Castleman氏病治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Janssen Biotech, Inc.
    • Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • EUSA Pharma（UK）Limited
    • Swedish Orphan Biovitrum AB
    • Grifols, SA
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Bristol-Myers Squibb Company
Product Code: MRR-4312A385A340

The Castleman Disease Treatment Market is projected to grow by USD 954.52 million at a CAGR of 14.01% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 334.15 million
Estimated Year [2025] USD 380.66 million
Forecast Year [2032] USD 954.52 million
CAGR (%) 14.01%

A strategic overview of Castleman disease clinical complexity and the evolving therapeutic and care delivery frameworks shaping treatment decisions

Castleman disease presents a complex clinical and operational challenge that spans immunology, oncology, and rare disease management. Patients experience a spectrum of presentations from unicentric forms amenable to localized intervention to multicentric and systemic variants that demand sustained multidisciplinary care. Diagnostic delays and heterogeneity in clinical presentation intensify unmet needs, while advances in understanding the central role of cytokine signaling have reframed therapeutic priorities across clinical practice.

Over the past decade, therapeutic pathways have moved from empiric use of broad immunosuppression and cytotoxic approaches toward targeted biologic interventions that alter disease trajectory for many patients. Alongside pharmacologic innovation, care delivery models have evolved to encompass home-based regimens, specialty clinic coordination, and integrated patient support mechanisms that address quality of life and adherence. For stakeholders focused on clinical impact and operational feasibility, the treatment landscape requires strategies that reconcile scientific progress with access, reimbursement, and real-world implementation realities.

The most significant shifts reshaping Castleman disease care arising from targeted biologics, biomarker-driven strategies, and novel care delivery models

Recent mechanistic and therapeutic advances have catalyzed transformative shifts across research, clinical practice, and patient support paradigms. A sharper focus on the interleukin-6 pathway and cytokine modulation has redirected research investments to biologics and monoclonal antibodies, while parallel efforts in biomarker discovery aim to stratify patients for more precise interventions and to identify those most likely to derive durable benefit. This scientific pivot is producing a cascade of downstream changes that affect trial design, comparator selection, and regulatory dialogue.

Concurrently, delivery innovation has accelerated. The rise of home administration, telemedicine-enabled follow-up, and integrated specialty clinic networks has reshaped patient touchpoints and adherence frameworks. These changes are accompanied by payer and provider adaptations that emphasize value-based contracting and outcomes-based evidence. Taken together, these shifts require stakeholders to re-evaluate clinical pathways, supply chain resilience, and commercial strategies to align with a landscape that prizes targeted efficacy, patient-centric delivery, and measurable real-world outcomes.

How changes in United States tariff policy in 2025 are influencing supply chains, sourcing strategies, and continuity of access for Castleman disease therapeutics

Tariff adjustments enacted in the United States during 2025 have introduced new considerations for manufacturers, distributors, and care providers involved in treating rare immune-mediated conditions. Even when core biologic agents themselves may be produced under specialized trade terms, ancillary inputs such as active pharmaceutical ingredients, single-use devices, packaging components, and cold-chain logistics are sensitive to cross-border cost shifts. As import duties and logistical surcharges change, stakeholders must reassess sourcing decisions and inventory strategies to preserve continuity of care for vulnerable patient cohorts.

In practice, these supply-side cost pressures can prompt manufacturers to explore nearshoring, alternative supplier qualification, or increased vertical integration to control critical nodes of the value chain. Health systems and specialty pharmacies respond by refining procurement cycles and expanding buffering capabilities to reduce the risk of treatment interruption. From a commercial perspective, negotiations around pricing, contracting, and patient assistance programs will need to incorporate the operational realities of higher landed costs and potential delays. Strategically, organizations that proactively map tariff exposures and build flexible sourcing models will be positioned to maintain access while managing margin implications and preserving treatment adherence for patients.

Deep segmentation insights explaining how treatment types, lines of therapy, distribution channels, and care settings shape clinical and commercial execution

A clear understanding of patient cohorts and therapeutic pathways is essential when interpreting treatment responses and planning commercial approaches. Treatment segmentation distinguishes between chemotherapy approaches and targeted biologics, with chemotherapy further analyzed across combination therapy and monotherapy modalities, and corticosteroid use delineated by agents such as dexamethasone and prednisone. This granularity clarifies where clinical practice favors broad immunosuppression compared to precision targeting, and it informs comparative safety and tolerability discussions that are central to clinician decision-making.

Line-of-therapy segmentation captures how interventions are positioned across first line, second line, and later-line settings, with first-line approaches further differentiated by combination therapy versus monotherapy strategies. Distribution channel distinctions between offline and online pathways reveal differences in patient access, dispensing workflows, and adherence supports. End-user analysis underscores where care is delivered-home care settings, hospitals, or specialty clinics-with further subdivision of home care into self-administration and visiting nurse services to reflect variations in patient independence, training needs, and monitoring intensity. Together, these segmentations enable a multidimensional view of the landscape that supports targeted clinical programs, optimized supply chain planning, and tailored patient services.

How regional differences across the Americas, Europe Middle East & Africa, and Asia-Pacific define access pathways, adoption patterns, and commercial approaches

Regional dynamics exert a powerful influence on clinical adoption, reimbursement strategy, and access pathways. In the Americas, specialized centers and established referral networks accelerate adoption of targeted biologics and support robust clinical trial activity, while payer frameworks and patient assistance programs shape out-of-pocket exposure and formulary positioning. This regional ecosystem tends to favor rapid dissemination of evidence into practice, although disparities in access persist across different care settings and population groups.

The Europe, Middle East & Africa region presents a heterogenous landscape where regulatory processes, reimbursement criteria, and health system structures vary widely. In several Western European markets, centralized expert networks and health technology assessment processes promote evidence-based adoption, whereas other markets within the region experience slower uptake due to resource constraints and distribution barriers. Meanwhile, Asia-Pacific markets combine rapid capacity expansion in biologic manufacturing with cost-sensitive payer environments; variations across countries drive diverse commercial approaches, ranging from local manufacturing partnerships to tiered pricing and digital engagement models aimed at improving access and patient monitoring.

Commercial and development strategies that companies are adopting to differentiate therapies, expand access, and build sustainable evidence generation programs

Leading commercial and development strategies in the Castleman disease space emphasize innovation across the value chain rather than a single point of differentiation. Companies are prioritizing durable clinical benefit through targeted mechanisms of action, expanding indication breadth through investigator-sponsored and registrational studies, and balancing lifecycle management with portfolio diversification to mitigate single-product risk. Strategic partnerships with manufacturing, clinical research organizations, and specialty pharmacies are common tactics to scale complex biologic production and to streamline patient access pathways.

Beyond pipeline and manufacturing considerations, successful organizations invest in patient support programs, real-world evidence generation, and clinician education to accelerate uptake and demonstrate value to payers. Pricing strategies increasingly reflect a blend of upfront list prices supplemented by outcomes-based agreements or risk-sharing models. At the same time, the potential entrance of biosimilar or alternative biologic competitors underscores the importance of differentiation through superior safety profiles, simplified administration, or demonstrable long-term outcomes in real-world settings.

Practical and prioritized recommendations for industry leaders to align clinical innovation, access strategies, and operational resilience for long-term success

Industry leaders should prioritize a set of integrated, actionable moves that align clinical efficacy with access and operational resilience. First, investment in diagnostic precision and biomarker programs will enable more accurate patient selection and stronger payer conversations, reducing uncertainty about comparative effectiveness. Second, diversifying manufacturing and supply partnerships, including regional production capacities and validated alternative suppliers, will mitigate exposure to tariff-driven cost shifts and logistical disruption.

Third, building robust patient support infrastructure that spans home administration training, visiting nurse services, and digital adherence tools will enhance real-world persistence and clinical outcomes. Fourth, engaging payers early to design outcomes-based or value-based contracting arrangements can bridge evidence gaps and unlock coverage while aligning incentives. Finally, companies should adopt an evidence continuum approach that combines randomized data with real-world registries and patient-reported outcomes to support long-term positioning and lifecycle strategy.

A rigorous mixed-methods research approach combining clinical literature, stakeholder interviews, and real-world data triangulation to ensure robust insights

The findings presented here derive from a mixed-methods research approach designed to balance clinical rigor with real-world applicability. The methodology integrates a comprehensive review of peer-reviewed literature and clinical trial registries with qualitative interviews conducted with treating clinicians, specialty pharmacists, and payer representatives to capture practice patterns and reimbursement drivers. Real-world data sources and observational registry evidence were analyzed to validate treatment pathways and to contextualize adherence and safety profiles outside controlled trials.

Data triangulation and cross-validation were employed to ensure robustness, with iterative expert consultations used to interpret ambiguous or inconsistent signals. Key variables such as treatment modality, line of therapy, care setting, and distribution channel were coded consistently to allow comparative analysis across data streams. Throughout the research process, ethical and data governance standards were observed, and findings were synthesized to provide actionable insights that remain grounded in current clinical practice and operational realities.

A concise synthesis of evidence and strategic direction to convert therapeutic innovation into sustained clinical and operational impact for Castleman disease

In conclusion, advances in targeted biologic therapies and evolving care delivery models are reshaping the Castleman disease treatment landscape in ways that create both opportunity and obligation for stakeholders. Scientific progress around cytokine modulation has delivered meaningful improvements for many patients, but structural challenges related to access, supply chain resilience, and variable reimbursement environments remain. Addressing these challenges requires coordinated action across clinical, commercial, and operational domains to ensure that therapeutic gains translate into sustained patient benefit.

Looking ahead, organizations that integrate biomarker-driven patient selection, resilient sourcing strategies, payer-aligned value demonstration, and patient-centric delivery models will be best positioned to convert innovation into real-world impact. A holistic strategy that spans development, market access, and post-approval evidence generation offers the clearest pathway to improving outcomes for patients living with Castleman disease while maintaining commercial viability and operational sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical trial advancements in investigational siltuximab biosimilars expanding treatment options for multicentric Castleman disease
  • 5.2. Growing adoption of precision medicine approaches leveraging biomarkers to tailor Castleman disease therapy regimens
  • 5.3. Rising investment in small molecule inhibitors targeting JAK-STAT signaling for refractory Castleman disease management
  • 5.4. Increasing collaboration between academic centers and biopharma firms accelerating novel Castleman disease drug development
  • 5.5. Regulatory approvals of next generation anti-IL-6 receptor agents transforming treatment landscape for Castleman patients
  • 5.6. Enhanced patient access programs and reimbursement strategies improving affordability of rare disease therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Castleman Disease Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Combination Therapy
    • 8.1.2. Monotherapy
  • 8.2. Corticosteroids
    • 8.2.1. Dexamethasone
    • 8.2.2. Prednisone
  • 8.3. Siltuximab
  • 8.4. Tocilizumab

9. Castleman Disease Treatment Market, by Line Of Therapy

  • 9.1. First Line
    • 9.1.1. Combination Therapy
    • 9.1.2. Monotherapy
  • 9.2. Later Lines
  • 9.3. Second Line

10. Castleman Disease Treatment Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Castleman Disease Treatment Market, by End User

  • 11.1. Home Care Settings
    • 11.1.1. Self Administration
    • 11.1.2. Visiting Nurse Services
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Castleman Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Castleman Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Castleman Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Janssen Biotech, Inc.
    • 15.3.2. Hoffmann-La Roche Ltd
    • 15.3.3. Pfizer Inc.
    • 15.3.4. EUSA Pharma (UK) Limited
    • 15.3.5. Swedish Orphan Biovitrum AB
    • 15.3.6. Grifols, S.A.
    • 15.3.7. AbbVie Inc.
    • 15.3.8. Takeda Pharmaceutical Company Limited
    • 15.3.9. Novartis AG
    • 15.3.10. Bristol-Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY H